Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01967381 · ClinicalTrials.gov registry record · Early Phase 1
Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse
A Early Phase 1 study of Methamphetamine-dependence and Methamphetamine Abuse, sponsored by University of Kentucky.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT01967381: Completed Early Phase 1 study of Methamphetamine-dependence and Methamphetamine Abuse, sponsored by University of Kentucky.
NCT01967381 is a Early Phase 1 study of Methamphetamine-dependence and Methamphetamine Abuse that has completed, run by University of Kentucky. The registered enrollment target is 24 participants, below the 105-participant average among 18 other Methamphetamine-dependence trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01967381, a Early Phase 1 study of Methamphetamine-dependence and Methamphetamine Abuse, has completed, sponsored by University of Kentucky.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The research proposed in this application will determine the initial efficacy, safety and tolerability of a novel drug combination, oxazepam (Serax®) and naltrexone (Revia®), as a pharmacotherapy for methamphetamine (Desoxyn®) dependence. A rigorous, inpatient human laboratory study will be conducted. The proposed study is innovative and important because it will provide the impetus for the conduct of double blind, placebo-controlled trials to further demonstrate the efficacy of combined oxazepam and naltrexone for managing methamphetamine dependence.
Primary Outcome
The reinforcing effects of methamphetamine will be determined using a self-administration procedure in which subjects choose to take previously sampled doses. Reinforcing effects are measured during maintenance on placebo, oxazepam (Serax®), naltrexone (Revia®), and oxazepam and naltrexone combined.
Conditions Studied
Interventions
- DRUG Methamphetamine (Desoxyn®)
Study Locations (1)
Kentucky
- University of Kentucky Medical Center - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-10 |
| Est. Completion | 2018-09 |
| Phase | Early Phase 1 |
What the finished NCT01967381 record still lists
NCT01967381 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 105-participant average among 18 other Methamphetamine-dependence trials with a reported enrollment target (77% lower).
The record links to 2 conditions, with Methamphetamine-dependence appearing as the primary indexed condition, and to 1 intervention - of which Methamphetamine (Desoxyn®) is the first listed.
NCT01967381 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT01967381 about?
NCT01967381 is a clinical study titled "Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse". The research proposed in this application will determine the initial efficacy, safety and tolerability of a novel drug combination, oxazepam (Serax®) and naltrexone (Revia®), as a pharmacotherapy for methamphetamine (Desoxyn®) dependence. A rigorous, inpatient human laboratory study will be conducte...
What is the current status of trial NCT01967381?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2013-10. Estimated completion is 2018-09.
What conditions does trial NCT01967381 study?
This clinical trial studies the following conditions: Methamphetamine-dependence, Methamphetamine Abuse.
What interventions are being tested in trial NCT01967381?
The interventions under investigation include: Methamphetamine (Desoxyn®) (DRUG).
Who is sponsoring clinical trial NCT01967381?
This trial is sponsored by University of Kentucky, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01967381 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Methamphetamine-dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01967381's enrollment target sits among peer trials
24 13th of 18 higher than 6 of 18 other Methamphetamine-dependence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Methamphetamine-dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT)
RECRUITING · Early Phase 1
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder
RECRUITING · Phase 3
-
Encouraging Abstinence Behavior in a Drug Epidemic: Optimizing Dynamic Incentives
RECRUITING · NA
-
rTMS for Craving in Methamphetamine Use Disorder
RECRUITING · NA
-
Creatine for Depressed Male and Female Methamphetamine Users
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia